PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Visiongain

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Smoking Cessation Drugs Market to Reach $2.4 Billion in 2012 Predicts Visiongain Report - A new report by visiongain predicts that the world market for smoking cessation medicines will reach $2.4 billion for 2012 - Visiongain.com
Smoking Cessation Drugs Market to Reach $2.4 Billion in 2012 Predicts Visiongain Report

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/04/16 - A new report by visiongain predicts that the world market for smoking cessation medicines will reach $2.4 billion for 2012 - Visiongain.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

That revenue forecast appears in Smoking Cessation Drugs: World Market Prospects 2012-2022, published in April 2012. Visiongain is a business information provider based in London, UK.

Visiongain’s study predicts that the smoking cessation drug market will grow during the forecast period 2012 to 2022. Rising incidence and prevalence of smoking will stimulate revenue growth, especially in developing countries. The scope of the market is broadening, with millions of smokers wanting to stop smoking.

From 2012 to 2022, the pharmaceutical industry will improve treatments to stop smoking. The R&D pipeline is promising. New formulations and generics will be important too. Innovations in drug delivery and rising demand in developing countries will also stimulate the industry and market.

Kritika Chaudhari, a pharmaceutical industry analyst at visiongain, said: “In general, smoking cessation drugs suffer from two drawbacks at present. First, they have notable side effects. Second, is the challenge of smokers relapsing after treatment with anti-smoking medication. These difficulties are being recognised; addressing them will benefit the smoking cessation drugs market from 2012 to 2022.”

Visiongain’s report provides revenue forecasts to 2022 at world market, submarket, product and national level. It forecasts world sales for the following submarkets:

• Over-the-counter (OTC) smoking cessation products;
• Prescription (Rx) drugs;
• Nicotine replacement therapy (NRT);
• Nicotine receptor partial agonists;
• Antidepressant therapy segment.

That investigation forecasts sales of leading drugs in the smoking treatments market, including Nicorette, Nicotinell and Champix/Chantix. Research, data and analyses cover activities of Pfizer, GSK, Novartis and other pharmaceutical companies.

The analysis includes researching the R&D pipeline, interviewing authorities on the industry and forecasting revenues in leading national markets. Countries analysed are the US, Japan, the EU5, China and India. Smoking Cessation Drugs: World Market Prospects 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the visiongain report Smoking Cessation Drugs: World Market Prospects 2012-2022 please visit the website.

About Visiongain
Visiongain (visiongain.com) is one of the fastest growing and most innovative independent business intelligence companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters and management reports focusing on the Energy, Telecoms, Pharmaceuticals, Defence, Aviation and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Visiongain

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Smoking Cessation Drugs Market to Reach $2.4 Billion in 2012 Predicts Visiongain Report

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sara Peerun - Visiongain.com 
+44(0)20 7336 6100 sara.peerun[.]visiongainglobal.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Visiongain securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Visiongain / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)